Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 1.3% – Time to Sell?

Ernexa Therapeutics Inc. (NASDAQ:ERNA)’s stock price traded down 1.3% on Friday . The stock traded as low as $1.48 and last traded at $1.50. 73,697 shares traded hands during mid-day trading, an increase of 45% from the average session volume of 50,964 shares. The stock had previously closed at $1.52.

Ernexa Therapeutics Trading Down 1.3%

The firm has a fifty day simple moving average of $1.90 and a two-hundred day simple moving average of $2.95. The stock has a market cap of $11.51 million, a PE ratio of -0.18 and a beta of 5.42.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.61) EPS for the quarter.

Hedge Funds Weigh In On Ernexa Therapeutics

A hedge fund recently raised its stake in Ernexa Therapeutics stock. Geode Capital Management LLC grew its position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 257,310 shares of the company’s stock after purchasing an additional 236,875 shares during the quarter. Geode Capital Management LLC owned approximately 4.76% of Ernexa Therapeutics worth $76,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.